AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10775708 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective memory of Korsakoff patients;
Number of subjects: 0
Study 8679352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil low dose (1 microgram kg‐1 i.v. over 1 min and an infusion of 0.2 microgram kg‐1 min‐1)
Number of subjects: 60
Study 8679352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil medium dose (2.5 micrograms kg‐1 and 0.5 microgram kg‐1 min‐1)
Number of subjects: 60
Study 8679352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil high dose (5 micrograms kg‐1 and 1 microgram kg‐1 min‐1)
Number of subjects: 60
Study 8679352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (all doses)
Number of subjects: 60
Study 2056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (75 mg.) BCG regimen
Number of subjects: 126
Study 2056600 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone (control group)
Number of subjects: 126
Study 6192650 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 and H2 receptor antagonists (used separately and in combination)
Number of subjects: 0
Study 6192650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of H1 plus H2 antagonist
Number of subjects: 0
Study 6192650 — intervention group
Group type: COMPARATOR
Intervention: H2 receptor antagonists
Number of subjects: 0
Study 6192650 — intervention group
Group type: COMPARATOR
Intervention: Potent H1 blocker alone
Number of subjects: 0
Study 30586670 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS prior to treadmill training three times per week for 3 weeks
Number of subjects: 14
Study 30586670 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS before treadmill training
Number of subjects: 14
Study 29715698 — intervention group
Group type: EXPERIMENTAL
Intervention: ETX + 1,25‐(OH) 2 D 3 (1 ng/mL)
Number of subjects: 4
Study 29715698 — intervention group
Group type: COMPARATOR
Intervention: ETX
Number of subjects: 4
Study 29715698 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐(OH) 2 D 3 (1 ng/mL)
Number of subjects: 4
Study 26813210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch only (n=241)
Number of subjects: 1086
Study 26813210 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline only (n=424)
Number of subjects: 1086
Study 26813210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (C‐NRT) (n=421)
Number of subjects: 1086
Study 24507484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held NB-UVB phototherapy
Number of subjects: 54
Study 24507484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed)
Number of subjects: 54
Study 22684521 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 synthetic long-peptide vaccine (1-2 vaccinations)
Number of subjects: 9
Study 22684521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20711437 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory exercises (GMS), twice a week for 12 weeks
Number of subjects: 46
Study 20711437 — intervention group
Group type: COMPARATOR
Intervention: Strength exercises (GST), twice a week for 12 weeks
Number of subjects: 46
Study 17940245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate
Number of subjects: 40
Study 17940245 — intervention group
Group type: COMPARATOR
Intervention: Diazepam infusion
Number of subjects: 40
Study 15881474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 444
Study 12556062 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and on-site screening intervention
Number of subjects: 94
Study 12556062 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention status
Number of subjects: 94
Study 10628626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg)
Number of subjects: 0
Study 8953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vanadyl sulfate (VOSO4) 0.5 mg/kg/day
Number of subjects: 31
Study 8953340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8953340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vanadyl sulfate (VOSO4)
Number of subjects: 31
Study 1945604 — intervention group
Group type: COMPARATOR
Intervention: Soy formula (group A)
Number of subjects: 102
Study 1945604 — intervention group
Group type: EXPERIMENTAL
Intervention: Khitchri and yogurt diet (group B)
Number of subjects: 102
Study 6812154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2 mixture
Number of subjects: 0
Study 6812154 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of air (placebo control)
Number of subjects: 0
Study 29143550 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (IV doses: 30, 100, or 600 mg; SC doses: 60 or 300 mg)
Number of subjects: 28
Study 29143550 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (IV doses)
Number of subjects: 28
Study 29143550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV)
Number of subjects: 28
Study 29143550 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (SC doses)
Number of subjects: 28
Study 29143550 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 28
Study 29143550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28666704 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 16
Study 28666704 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 16
Study 25482680 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra, 100 mg/day for 14 days
Number of subjects: 40
Study 25482680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23833156 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician language (motivational interviewing‐adherent statements, reflections, empathy)
Number of subjects: 63
Study 23833156 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more change talk statements
Number of subjects: 63
Study 23833156 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero or one change talk statements
Number of subjects: 63
Study 23833156 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy and motivational interviewing spirit
Number of subjects: 63
Study 23833156 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy
Number of subjects: 63
Study 21094099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine gel-soaked Falope rings
Number of subjects: 96
Study 21094099 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac suppository
Number of subjects: 96
Study 21094099 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesic
Number of subjects: 96
Study 19723645 — intervention group
Group type: EXPERIMENTAL
Intervention: High p27 expression (p27-positive tumor cells >70%)
Number of subjects: 483
Study 19723645 — intervention group
Group type: COMPARATOR
Intervention: Low p27 expression
Number of subjects: 483
Study 17592295 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 455
Study 15459412 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated real time PCR
Number of subjects: 233
Study 15459412 — intervention group
Group type: COMPARATOR
Intervention: Virus culture
Number of subjects: 233
Study 11296175 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 41
Study 11296175 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study 9260731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole 5 mg twice daily
Number of subjects: 0
Study 9260731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole 10 mg twice daily
Number of subjects: 0
Study 9260731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9260731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole (5 or 10 mg)
Number of subjects: 0
Study 1437338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (3 doses)
Number of subjects: 95
Study 1437338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (2 doses)
Number of subjects: 95
Study 1437338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (1 dose)
Number of subjects: 95
Study 3873877 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (50 micrograms, total 300 micrograms) administered intradermally (i.d.) over 10 days
Number of subjects: 38
Study 3873877 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.d. injection of 50 micrograms betamethasone 24 hours prior to anti-IgE challenge
Number of subjects: 38
Study 3873877 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of betamethasone 2 hours prior to and together with anti-IgE
Number of subjects: 38
Study 3873877 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone administered i.d. 30 minutes following anti-IgE challenge
Number of subjects: 38
Study 31102578 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic extraction with a removable appliance
Number of subjects: 16
Study 31102578 — intervention group
Group type: COMPARATOR
Intervention: Traditional extraction
Number of subjects: 16
Study 30358519 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 28
Study 30358519 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 28
Study 26510505 — intervention group
Group type: EXPERIMENTAL
Intervention: Early chemotherapy with docetaxel in addition to androgen deprivation therapy (ADT)
Number of subjects: 0
Study 26510505 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 0
Study 24743550 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infected children
Number of subjects: 700
Study 24743550 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated malaria
Number of subjects: 700
Study 24743550 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malaria anemia
Number of subjects: 700
Study 24743550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral malaria
Number of subjects: 700
Study 21940058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban administration (10 μg/kg)
Number of subjects: 453
Study 21940058 — intervention group
Group type: COMPARATOR
Intervention: Saline control (10 mL)
Number of subjects: 453
Study 20658155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg b.d. for 14 days)
Number of subjects: 14
Study 20658155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18327671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor exemestane alone
Number of subjects: 0
Study 18327671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor exemestane in combination with antiestrogen tamoxifen
Number of subjects: 0
Study 16884980 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 to 1.0 minimum alveolar concentration, n = 15)
Number of subjects: 25
Study 16884980 — intervention group
Group type: COMPARATOR
Intervention: Urapidil (weight-adjusted boli, n = 10)
Number of subjects: 25
Study 12800412 — intervention group
Group type: EXPERIMENTAL
Intervention: Taizhi'an (TZA)
Number of subjects: 300
Study 12800412 — intervention group
Group type: COMPARATOR
Intervention: Half-dose Fenofibrate plus Taizhi'an
Number of subjects: 300
Study 12800412 — intervention group
Group type: COMPARATOR
Intervention: Full-dose Fenofibrate
Number of subjects: 300
Study 12800412 — intervention group
Group type: COMPARATOR
Intervention: Half-dose Simvastatin plus Taizhi'an
Number of subjects: 300
Study 12800412 — intervention group
Group type: COMPARATOR
Intervention: Full-dose Simvastatin
Number of subjects: 300
Study 12800412 — intervention group
Group type: COMPARATOR
Intervention: Zhibituo
Number of subjects: 300
Study 12800412 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang
Number of subjects: 300
Study 10959019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1997 International Liaison Committee on Resuscitation (ILCOR) guidelines
Number of subjects: 0
Study 10959019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1992 European Resuscitation Council (ERC) guidelines
Number of subjects: 0
Study 10959019 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association 'call first' version of the 1997 ILCOR statement
Number of subjects: 0
Study 10959019 — intervention group
Group type: COMPARATOR
Intervention: All methods
Number of subjects: 0
Study 8626839 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily somatropin treatment (0.3 mg/kg.week)
Number of subjects: 0
Study 1295265 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate walking condition
Number of subjects: 40
Study 1295265 — intervention group
Group type: COMPARATOR
Intervention: No-exercise condition
Number of subjects: 40
Study 7400374 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg plus reserpine 0.25 mg
Number of subjects: 57
Study 7400374 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg plus reserpine 0.125 mg
Number of subjects: 57
Study 30528307 — intervention group
Group type: EXPERIMENTAL
Intervention: B + O suppository
Number of subjects: 50
Study 30528307 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 50
Study 28320765 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 149
Study 28320765 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 149
Study 28320765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 25144853 — intervention group
Group type: EXPERIMENTAL
Intervention: GutsyGum(tm)
Number of subjects: 24
Study 25144853 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 24
Study 24432622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardura 4 mg qd for 8 weeks
Number of subjects: 87
Study 24432622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardura 4 mg + Tolterodine L‐Tartrate Tablets 4 mg qd for 8 weeks
Number of subjects: 87
Study 21336952 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial gravity (AG) with ergometric exercise (40 W) for 30 min twice per day
Number of subjects: 12
Study 19121597 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA with correction factor for fat mass
Number of subjects: 162
Study 19121597 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected DXA estimates
Number of subjects: 162
Study 19121597 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected DXA estimates
Number of subjects: 162
Study 17722822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 79
Study 17722822 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 79
Study 17722822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 79
Study 16988136 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement containing folic acid (400 microg) with iron (18 mg)
Number of subjects: 71
Study 16988136 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin supplement containing folic acid (400 microg) without iron
Number of subjects: 71
Study 14673680 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sympathetic block (ESB) at level T3
Number of subjects: 60
Study 14673680 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sympathetic block (ESB) at level T2
Number of subjects: 60
Study 14673680 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative condition
Number of subjects: 60
Study 11228756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 48
Study 11228756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8523049 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 960
Study 8523049 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 960
Study 8523049 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 960
Study 2188590 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifloxacin 200 mg twice a day
Number of subjects: 0
Study 2188590 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifloxacin 400 mg twice a day
Number of subjects: 0
Study 2188590 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 0
Study 7290416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribostamycin sulphate (1000‐2000 mg i.m.)
Number of subjects: 20
Study 7290416 — intervention group
Group type: COMPARATOR
Intervention: Gentamycin (160‐240 mg i.m.)
Number of subjects: 20
Study 7290416 — intervention group
Group type: COMPARATOR
Intervention: Sodium cephalotin (4‐8 g i.v.)
Number of subjects: 20
Study 31698290 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning
Number of subjects: 60
Study 31698290 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning
Number of subjects: 60
Study 30268512 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and internal fixation of a 31A2 unstable pertrochanteric fracture with a cephalomedullary nail with distal locking through the proximal guide
Number of subjects: 32
Study 26628607 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 50 mg twice daily for 6 weeks
Number of subjects: 43
Study 26628607 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 43
Study 26628607 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 50 mg twice daily for 6 weeks (subgroup with swollen joint count ≤ 1)
Number of subjects: 43
Study 26628607 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks (subgroup with swollen joint count ≤ 1)
Number of subjects: 43
Study 26552348 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day standard regimen of triple therapy for peptic ulcer: omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, twice per day
Number of subjects: 132
Study 23981613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 218
Study 23981613 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 218
Study 20359549 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 1279
Study 20359549 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 1279
Study 18308147 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with anthracyclines and taxanes
Number of subjects: 0
Study 18308147 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (eg, trastuzumab and lapatinib)
Number of subjects: 0
Study 16341366 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 30
Study 16341366 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 30
Study 16341366 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 30
Study 12552347 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi
Number of subjects: 29
Study 12552347 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-sestamibi in patients with CAD
Number of subjects: 29
Study 10626563 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a total dose of 6 IU/m2/day (0.067 mg/kg/day) and ethinyloestradiol at a dose of 0.05 μg/kg/day
Number of subjects: 87
Study 10626563 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a dose of 4 IU/m2/day (0.045 mg/kg/day) for group A, switched to 6 IU/m2/day for group B, and switched to 8 IU/m2/day for group C
Number of subjects: 87
Study 8534728 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vancomycin with ceftazidime
Number of subjects: 120
Study 8534728 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vancomycin with ceftazidime
Number of subjects: 120
Study 8534728 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous teicoplanin with ceftazidime
Number of subjects: 120
Study 8534728 — intervention group
Group type: COMPARATOR
Intervention: Intermittent teicoplanin with ceftazidime
Number of subjects: 120
Study 1685942 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol (200 mg once daily)
Number of subjects: 571
Study 1685942 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 571
Study 7036150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (5 microgram HBsAg per 1ml dose, 3 subcutaneous doses at one-month intervals)
Number of subjects: 505
Study 7036150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 505
Study 7036150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (V)
Number of subjects: 505
Study 31630323 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training programmes
Number of subjects: 5
Study 30431664 — intervention group
Group type: EXPERIMENTAL
Intervention: Umifenovir (Arbidol)
Number of subjects: 18
Study 27190374 — intervention group
Group type: EXPERIMENTAL
Intervention: Two high flux dialyzers in parallel (blood flow ≥350 mL/min, dialysate flow 800 mL/min)
Number of subjects: 32
Study 27190374 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis using one high flux dialyzer (blood flow ≥350 mL/min, dialysate flow of 800 mL/min)
Number of subjects: 32
Study 27190374 — intervention group
Group type: EXPERIMENTAL
Intervention: Two high flux dialyzers in parallel
Number of subjects: 32
Study 25684674 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet (Group A)
Number of subjects: 268
Study 25684674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (Group B)
Number of subjects: 268
Study 25684674 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment with antispasmodics or antidiarrhoeal drugs (Group C)
Number of subjects: 268
Study 24252596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) at 85-90% of VO2peak, 3 times weekly for 12 weeks, followed by 2 times weekly for 40 weeks
Number of subjects: 70
Study 24252596 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet (800-1000 kcal/day) for 12 weeks followed by weight maintenance combined with supervised AIT twice weekly for 40 weeks
Number of subjects: 70